ライフサイエンスコーパス: LUTS

1 LUTS cases had at least three of these symptoms: nocturi

2 LUTS cases were defined as men who reported surgery for

3 LUTS were common both before and after RTx as measured b

4 LUTS/BPH is an independent risk factor for sexual dysfun

5 ejaculation frequency in early adulthood and LUTS.

6 - for the prevention or treatment of BPH and LUTS have yet to be performed.

7 e for the prevention or treatment of BPH and LUTS have yet to be performed.

8 antly increased risks of symptomatic BPH and LUTS include obesity and consumption of meat and fat.

9 for the prevention and treatment of BPH and LUTS while positively affecting other systemic parameter

10 for the prevention and treatment of BPH and LUTS, nutritional modifications may have a healthy lifes

11 ially alter the risks of symptomatic BPH and LUTS.

12 standard treatments for symptomatic BPH and LUTS.

13 ity - both of which inversely effect BPH and LUTS.

14 and dietary supplements in men with BPH and LUTS.

15 ow-up, and between 5-year intake changes and LUTS progression.

16 f weight loss in obese men with diabetes and LUTS and dietary modification has also been shown to be

17 may contribute to the link between diet and LUTS because of their anti-inflammatory potential, and 3

18 he association between lifestyle factors and LUTS and the effect of lifestyle modification on the dev

19 ute associations between beverage intake and LUTS in the Boston Area Community Health (BACH) cohort (

20 olume, prostate-specific antigen levels, and LUTS as well as rapid decreases in peak flow rates (thro

21 prescription and over-the-counter NSAIDs and LUTS among 1,974 men and 2,661 women in the Boston Area

22 upport for an association between NSAIDs and LUTS.

23 uency, surgery for an enlarged prostate, and LUTS.

24 Information on prostate surgery and LUTS was updated every 2 years.

25 oda, had higher symptom scores, urgency, and LUTS progression.

26 ve been proposed for the association between LUTS and male sexual dysfunction.

27 d strong evidence for an association between LUTS, erectile dysfunction and ejaculatory dysfunction.

28 Recent evidence of an association between LUTS/BPH and sexual dysfunction will be reviewed, as wel

29 Owing to the link between LUTS/BPH and male sexual dysfunction, patients presentin

30 the mechanism(s) underlying the link between LUTS/BPH and male sexual dysfunction.

31 ationship between metabolic syndrome and BPH/LUTS, indicating a common cause.

32 the components of metabolic syndrome and BPH/LUTS.

33 ocuses on the use of PDE5 inhibitors for BPH/LUTS treatment and highlights the clinical significance.

34 and well tolerated treatment option for BPH/LUTS.

35 kers resulted in greater improvements in BPH/LUTS than did either drug alone.

36 osphate/PDE5 pathway in the treatment of BPH/LUTS deserve further investigations.

37 activity, appear to decrease the risk of BPH/LUTS.

38 ay have an additive beneficial effect on BPH/LUTS compared with monotherapy.

39 t in the use of PDE5 inhibitors to treat BPH/LUTS.

40 tion to other conditions that may be causing LUTS.

41 rvoirs, but the role of infection in chronic LUTS is unknown.

42 ype 5 inhibitors in patients with coexisting LUTS and erectile dysfunction.

43 r age, comorbidities, and lifestyle factors, LUTS have been clearly demonstrated to be an independent

44 linical trials of antiinflammatory drugs for LUTS have been largely unsuccessful, the role of inflamm

45 ons to limit caffeinated beverage intake for LUTS, and in men, they suggest benefits of citrus juice

46 odds ratios and 95% confidence intervals for LUTS, voiding symptoms, storage symptoms, and nocturia.

47 uidelines as the first-line intervention for LUTS.

48 sed to identify patients at highest risk for LUTS after RTx.

49 to determine if patients at highest risk for LUTS could be predicted by validated questionnaires or o

50 physical activity level and a lower risk for LUTS or progression of LUTS, 2) certain specific nutrien

51 lopment of a urine-based diagnostic test for LUTS.

52 as a minimally invasive surgical therapy for LUTS associated with benign prostatic hyperplasia seems

53 dditional studies of combination therapy for LUTS/BPH, sexual dysfunction, and other age-associated c

54 because medical and surgical treatments for LUTS/BPH are commonly associated with sexual side effect

55 nce (> or = 102 cm) were more likely to have LUTS compared with men with a smaller waist circumferenc

56 p to 15% to 25% of men aged 50-65 years have LUTS of sufficient severity to interfere with their qual

57 suggestive of benign prostatic hyperplasia (LUTS/BPH).

58 he treatment of benign prostatic hyperplasia/LUTS can be properly assessed.

59 elling men with benign prostatic hyperplasia/LUTS.

60 n these hormones, and the rates of change in LUTS, maximum urinary flow rate, and prostate volume.

61 time were associated with rapid increases in LUTS and rapid decreases in maximum flow rate.

62 es regarding the outcome of thermotherapy in LUTS/BPH patients.

63 ios and 95% confidence intervals of incident LUTS (from no or a low International Prostate Symptom Sc

64 ypertension, and smoking history (irritative LUTS: OR = 2.00, 95% CI: 1.04, 3.82; peak flow rate: OR

65 likely to have rapid increases in irritative LUTS (odds ratio (OR) = 2.14, 95% confidence interval (C

66 s suggest that rapid increases in irritative LUTS and rapid decreases in peak flow rates may be due t

67 id increases in prostate volume, obstructive LUTS, or prostate-specific antigen levels.

68 >/=15; n = 5,790 cases in 24,715 men) and of LUTS progression (from modest IPSS of 8-14 to severe IPS

69 life will demand that we unlock the cause of LUTS secondary to BPH with the goal of prevention as the

70 ially influence the development or course of LUTS.

71 tions may contribute to later development of LUTS, although confirmation in additional population set

72 terations and support objective diagnosis of LUTS.

73 ssion, understanding that the improvement of LUTS relief should be weighed with the potential risks o

74 are important steps in medical management of LUTS.

75 ine intake at baseline increased the odds of LUTS progression in men (coffee: >2 cups/day vs. none, o

76 intake was associated with 50% lower odds of LUTS progression in men (P = 0.02).

77 The odds of LUTS were lower for men who were obese at age 25 years c

78 may be associated with a lower prevalence of LUTS later in life, whereas weight gain and central adip

79 sibly associated with a higher prevalence of LUTS.

80 between baseline intakes and progression of LUTS at 5-year follow-up, between follow-up intakes and

81 and a lower risk for LUTS or progression of LUTS, 2) certain specific nutrients or dietary factors m

82 ication on the development or progression of LUTS.

83 may decrease the incidence or progression of LUTS.

84 ay inhibit the development or progression of LUTS.

85 The hazard ratios of LUTS incidence and progression comparing current use to

86 s to determine the frequency and severity of LUTS in RTx patients and to determine if patients at hig

87 eness of PDE5 inhibitors in the treatment of LUTS secondary to BPH.

88 the first characterization and validation of LUTS urinary metabolites and pathways to support the fut

89 with laboratory markers specific for BPH or LUTS is currently inadequate.

90 t in men with urinary incontinence and other LUTS.

91 tween over-the-counter NSAID use and overall LUTS among women with a history of arthritis (odds ratio

92 IDs (compared with no NSAID use) and overall LUTS, voiding symptoms, or nocturia in men or women.

93 t only for potentially improving or reducing LUTS but also for cardiovascular and overall health.

94 ion for patients presenting with BPH-related LUTS, and suggest novel treatment strategies.

95 all been shown to be effective in relieving LUTS/BPH independent of prostate size.

96 so predictive of moderate to severe post-RTx LUTS (relative risk, 2.9-5.9; P<0.02).

97 re predictive of moderate to severe post-RTx LUTS (relative risk, 4.1-18.0; P</=0.05).

98 enlarged prostate or high-moderate to severe LUTS (> or = 15 points on the American Urological Associ

99 were at increased risk of moderate to severe LUTS, including obstructive symptoms.

100 putative risk factors for moderate to severe LUTS, including subcategories of obstructive and irritat

101 l history risk factors in moderate to severe LUTS, including the subcategories of obstructive and irr

102 ions between BPH with clinically significant LUTS, the metabolic syndrome, inflammation, alterations

103 acological treatment options for symptomatic LUTS/BPH on sexual function.

104 Administration for treatment of symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, alfuzosin an

105 lower urinary tract [obstructive] symptoms (LUTS) may benefit from a similar discussion, understandi

106 Lower urinary tract symptoms (LUTS) are a common condition, particularly among older m

107 Lower urinary tract symptoms (LUTS) are a range of irritative or obstructive symptoms

108 Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

109 and associated lower urinary tract symptoms (LUTS) commonly affect older men.

110 Worldwide, lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) is a com

111 sk factors for lower urinary tract symptoms (LUTS) have focused on White populations.

112 ic hyperplasia/lower urinary tract symptoms (LUTS) in 2014.

113 in relation to lower urinary tract symptoms (LUTS) in a large case-control study nested within the He

114 n the cause of lower urinary tract symptoms (LUTS) in older men.

115 commonly cause lower urinary tract symptoms (LUTS) in the renal transplant (RTx) population.

116 en obesity and lower urinary tract symptoms (LUTS) in the Third National Health and Nutrition Examina

117 management for lower urinary tract symptoms (LUTS) is limited.

118 main cause of lower urinary tract symptoms (LUTS) may lead to acute urinary retention and need for B

119 g incidence of lower urinary tract symptoms (LUTS) which are increasing.

120 nlargement and lower urinary tract symptoms (LUTS), and it is not clear how sex steroid hormones cont

121 le factors and lower urinary tract symptoms (LUTS), and their relevance in men.

122 he etiology of lower urinary tract symptoms (LUTS), raising the possibility that use of nonsteroidal

123 asia (BPH) and lower urinary tract symptoms (LUTS), recent epidemiological studies suggest that modif

124 Chronic lower urinary tract symptoms (LUTS), such as urgency and incontinence, are common, esp

125 asia (BPH) and lower urinary tract symptoms (LUTS).

126 anisms causing lower urinary tract symptoms (LUTS).

127 include other lower urinary tract symptoms (LUTS).

128 asia (BPH) and lower urinary tract symptoms (LUTS).

129 ent of BPH and lower urinary tract symptoms (LUTS).

130 suffering from lower urinary tract symptoms (LUTS).

131 e treatment of lower urinary tract symptoms (LUTS).

132 icant BPH with lower urinary tract symptoms (LUTS).

133 ten results in lower urinary tract symptoms (LUTS).

134 rplasia and/or lower urinary tract symptoms (LUTS).

135 rived strains in cell culture suggested that LUTS-associated bacteria are within or extremely closely

136 These LUTS may be masked by low urine output and may pose risk

137 ion within the urinary system contributes to LUTS is unclear.

138 the role of inflammation as a contributor to LUTS remains an interesting hypothesis that requires fur

139 in general, inflammation was not related to LUTS or to benign prostatic hyperplasia progression.

140 ostate surgery could be safely used to treat LUTS/BPH patients.

141 hest BMI ever was positively associated with LUTS (odds ratio = 1.90, 95% confidence interval: 0.89,

142 systemic inflammation may be associated with LUTS and benign prostatic hyperplasia.

143 heart disease was positively associated with LUTS and with irritative symptoms.

144 e (>/=$30,000) was inversely associated with LUTS and with obstructive and irritative symptoms.

145 al care), statin use was not associated with LUTS incidence (hazard ratio = 1.02, 95% confidence inte

146 or diabetes were positively associated with LUTS, and high income (>/=$30,000) was inversely associa

147 : 1.22, 1.96) was positively associated with LUTS.

148 ions as the first-line treatment in men with LUTS.

149 gen content and tissue stiffness in men with LUTS.

150 ating obstructed from nonobstructed men with LUTS.

151 rospective study with eligible patients with LUTS and controls over a 3-year period, comparing routin

152 ling in their routine care for patients with LUTS.

153 ated with sexual side effects, patients with LUTS/BPH should be monitored for treatment-related sexua

154 The associations of statin drug use with LUTS incidence and progression were prospectively evalua